DK3302519T3 - Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom - Google Patents

Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom Download PDF

Info

Publication number
DK3302519T3
DK3302519T3 DK15807907.9T DK15807907T DK3302519T3 DK 3302519 T3 DK3302519 T3 DK 3302519T3 DK 15807907 T DK15807907 T DK 15807907T DK 3302519 T3 DK3302519 T3 DK 3302519T3
Authority
DK
Denmark
Prior art keywords
moubata
ornithodoros
complement
versus
inhibitor
Prior art date
Application number
DK15807907.9T
Other languages
English (en)
Inventor
Wynne H Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Priority claimed from PCT/EP2015/079172 external-priority patent/WO2016198133A1/en
Application granted granted Critical
Publication of DK3302519T3 publication Critical patent/DK3302519T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK15807907.9T 2014-06-06 2015-12-09 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom DK3302519T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
PCT/EP2015/079172 WO2016198133A1 (en) 2015-06-08 2015-12-09 Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease

Publications (1)

Publication Number Publication Date
DK3302519T3 true DK3302519T3 (da) 2022-02-28

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15728491.0T DK3151851T3 (da) 2014-06-06 2015-06-08 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
DK15807907.9T DK3302519T3 (da) 2014-06-06 2015-12-09 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15728491.0T DK3151851T3 (da) 2014-06-06 2015-06-08 Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme

Country Status (16)

Country Link
US (3) US11052129B2 (da)
EP (1) EP3151851B1 (da)
JP (2) JP7045133B2 (da)
KR (1) KR102439717B1 (da)
CN (1) CN106659767B (da)
AU (1) AU2015270396B2 (da)
BR (1) BR112016028446A2 (da)
CA (1) CA2951175A1 (da)
DK (2) DK3151851T3 (da)
ES (2) ES2906630T3 (da)
GB (1) GB201410116D0 (da)
IL (1) IL249237B (da)
MX (1) MX382757B (da)
PL (2) PL3151851T3 (da)
RU (1) RU2700932C2 (da)
WO (1) WO2015185760A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3464351A1 (en) * 2016-06-07 2019-04-10 Novartis AG Anti-c5 antibody for treating patients with complement c5 polymorphism
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
JP4772667B2 (ja) 2003-06-02 2011-09-14 エヴォルーテック・リミテッド 補体阻害剤
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
AU2011204483B2 (en) * 2010-01-08 2016-02-11 Volution Immuno Pharmaceuticals Sa EV576 for use in the treatment of viral infections of the respiratory tract
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes

Also Published As

Publication number Publication date
IL249237B (en) 2020-09-30
KR20170016893A (ko) 2017-02-14
EP3151851B1 (en) 2021-12-01
PL3302519T3 (pl) 2022-04-25
RU2016151179A3 (da) 2019-01-22
AU2015270396B2 (en) 2020-07-16
CA2951175A1 (en) 2015-12-10
JP2018516944A (ja) 2018-06-28
CN106659767A (zh) 2017-05-10
NZ727053A (en) 2023-10-27
WO2015185760A1 (en) 2015-12-10
US11052129B2 (en) 2021-07-06
DK3151851T3 (da) 2022-02-28
JP7045133B2 (ja) 2022-03-31
EP3151851A1 (en) 2017-04-12
ES2906632T3 (es) 2022-04-19
ES2906630T3 (es) 2022-04-19
IL249237A0 (en) 2017-02-28
MX382757B (es) 2025-03-13
RU2016151179A (ru) 2018-07-16
GB201410116D0 (en) 2014-07-23
US20170196936A1 (en) 2017-07-13
JP6767396B2 (ja) 2020-10-14
BR112016028446A2 (pt) 2017-10-24
MX2016016139A (es) 2017-07-28
KR102439717B1 (ko) 2022-09-02
US20180193417A1 (en) 2018-07-12
PL3151851T3 (pl) 2022-04-04
AU2015270396A1 (en) 2016-12-15
JP2017518316A (ja) 2017-07-06
CN106659767B (zh) 2022-08-30
US20210283221A1 (en) 2021-09-16
RU2700932C2 (ru) 2019-09-24

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3231444T3 (da) Ny behandling
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
IL256206A (en) Mct4 inhibitors for treating disease
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
HUE063528T2 (hu) Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis